In vivo efficacy characterization of CLL1-ADC. CLL1-ADC or CD33-ADC or IgG-ADC treatment (single dose, intraperitoneal injection) of (A) HL60 tumor cell derived subcutaneous tumors and (C) OCI-AML2–derived tumors. Average tumor volume and SEM from 8 individual tumor-bearing mice is plotted against time with CLL1-ADC treatment shown in blue/gray color, CD33-ADC treatment in red/orange color and IgG-ADC control treatment in green/light green color. Survival curves (B,D) from subcutaneous tumor model were determined by number of days taken for tumor to volume to reach >1000 mm³ from the day of implantation, which then resulted in sacrificing these mice. (E-F) CLL1-ADC treatment (Q1W×3 dosing, intraperitoneal injection) of HL60 tumor cell–derived orthotopic tumor-bearing NOD/SCID mice. Bone marrow and peripheral blood were harvested following ADC treatments, processed, and analyzed for percentage of human cell based on staining with human-specific CD45 and CD33 antibodies. Data from 6 to 8 individual mice are shown, the lines represent median values of each group, and error bars represent interquartile range (ie, 25th percentile and 75th percentile). *The group in which datasets are statistically significant (P < .05) relative to control treatment based on 1-way ANOVA analysis.